Compare · PRDS vs RLX
PRDS vs RLX
Side-by-side comparison of Pardes Biosciences Inc. (PRDS) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRDS and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.05B, about 4.6x PRDS ($657.5M).
- PRDS has more recent analyst coverage (3 ratings vs 2 for RLX).
- Company
- Pardes Biosciences Inc.
- RLX Technology Inc.
- Price
- $2.19+1.39%
- $1.97-1.99%
- Market cap
- $657.5M
- $3.05B
- 1M return
- -
- -9.01%
- 1Y return
- -
- -10.45%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 3
- 2
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao